Valuation: Annexon, Inc.

Market Cap 886M 767M 717M 656M 1.24B 84.54B 1.25B 8.41B 3.3B 42.29B 3.33B 3.26B 141B P/E 2026 *
-5.74x
P/E 2027 * -6.38x
Enterprise Value 792M 686M 641M 586M 1.1B 75.53B 1.12B 7.51B 2.95B 37.78B 2.97B 2.91B 126B EV / Sales 2026 *
-
EV / Sales 2027 * 14.7x
Free-Float
93.49%
Yield 2026 *
-
Yield 2027 * -
1 day-0.46%
1 week+5.79%
Current month+5.79%
1 month-9.26%
3 months-5.27%
6 months-4.26%
Current year+7.37%
1 week 5.26
Extreme 5.255
5.7
1 month 4.76
Extreme 4.76
6.58
Current year 4.46
Extreme 4.46
7.18
1 year 2.03
Extreme 2.03
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.61
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 58 01/12/2014
Director/Board Member 65 01/12/2014
Director/Board Member 67 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
2/19/26 A Free

Chief Technology Officer

312,500 0.2159%
2/19/26 A Free

Chief Executive Officer

1,250,000 0.8637%
2/19/26 A Free

Executive/Senior Manager

312,500 0.2159%
Change 5-day change 1-year change 3-year change Capi.($)
-0.37%+5.79%+128.39%+60.90% 886M
+4.21%+25.62%+77.96%+111.62% 68.12B
+0.50%+2.95%+34.94%+69.77% 55.18B
+2.78%+36.66%+23.00%+526.16% 28.63B
+0.57%+19.05%+57.08%+5.18% 23.99B
-0.93%+2.45%-16.89%-12.86% 23.53B
-0.35%+7.18%+44.14%-22.28% 18.45B
-2.04%+9.24%+31.14%+650.71% 16.44B
+7.26%+25.47%+221.03%+383.67% 15.83B
-2.05%-0.13%+40.40%+156.84% 13.4B
Average +0.84%+9.25%+64.12%+192.97% 26.44B
Weighted average by Cap. +1.54%+11.44%+54.26%+169.61%

Financials

2026 *2027 *
Net sales - 40.38M 34.96M 32.67M 29.86M 56.27M 3.85B 57.15M 383M 150M 1.93B 152M 148M 6.42B
Net income -188M -163M -152M -139M -263M -17.97B -267M -1.79B -702M -8.99B -708M -692M -29.94B -191M -165M -154M -141M -266M -18.2B -270M -1.81B -711M -9.11B -717M -701M -30.33B
Net Debt -94.47M -81.78M -76.44M -69.87M -132M -9.01B -134M -896M -352M -4.51B -355M -347M -15.01B -292M -253M -236M -216M -407M -27.84B -413M -2.77B -1.09B -13.93B -1.1B -1.07B -46.39B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
93
Date Price Change Volume
10/08/26 $5.390 -0.37% 1,958,043
07/08/26 $5.410 -3.39% 2,045,960
06/08/26 $5.600 +4.28% 3,049,250
05/08/26 $5.370 +0.75% 1,770,792
04/08/26 $5.330 +1.52% 2,561,996
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.390USD
Average target price
13.25USD
Spread / Average Target
+145.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock